0000950170-21-001392 | 10-Q | XBRL Viewer

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2021	Aug. 09, 2021
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Registrant Name	GoodRx Holdings, Inc.
Entity Central Index Key	0001809519
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	false
Entity Shell Company	false
Entity File Number	001-39549
Entity Tax Identification Number	47-5104396
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2701 Olympic
Entity Address, Address Line Two	Boulevard
Entity Address, City or Town	Santa Monica
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90404
City Area Code	855
Local Phone Number	268-2822
Trading Symbol	GDRX
Title of 12(b) Security	Class A Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		75,429,443
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		320,210,544

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 894,703	$ 968,691
Restricted cash	0	2,900
Accounts receivable, net	87,004	68,729
Prepaid expenses and other current assets	94,043	46,048
Total current assets	1,075,750	1,086,368
Property and equipment, net	22,105	23,057
Goodwill	320,196	261,116
Intangible assets, net	94,780	36,919
Capitalized software, net	31,996	19,800
Operating lease right-of-use assets	26,902	27,712
Deferred tax assets, net	12,971	13,117
Other assets	2,229	2,025
Total assets	1,586,929	1,470,114
Current liabilities
Accounts payable	18,378	10,291
Accrued expenses and other current liabilities	33,759	37,692
Current portion of debt	7,029	7,029
Operating lease liabilities, current	6,325	4,539
Total current liabilities	65,491	59,551
Debt, net	657,877	659,888
Operating lease liabilities, net of current portion	32,818	33,467
Other liabilities	6,349	5,849
Total liabilities	762,535	758,755
Commitments and contingencies (Note 8)
Stockholders' equity
Preferred stock, $0.0001 par value; 50,000 shares authorized and zero shares issued and outstanding at June 30, 2021 and December 31, 2020
Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, 72,054 and 63,071 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively; and Class B: 1,000,000 shares authorized, 323,339 and 328,589 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	39	39
Additional paid-in capital	2,182,079	2,101,773
Accumulated deficit	(1,357,724)	(1,390,453)
Total stockholders' equity	824,394	711,359
Total liabilities and stockholders' equity	$ 1,586,929	$ 1,470,114

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Class A
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	72,054,000	63,071,000
Common stock, shares outstanding	72,054,000	63,071,000
Common Class B
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	323,339,000	328,589,000
Common stock, shares outstanding	323,339,000	328,589,000

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue	$ 176,635	$ 123,295	$ 337,066	$ 256,703
Costs and operating expenses:
Cost of revenue, exclusive of depreciation and amortization presented separately below	11,090	6,824	21,518	12,843
Product development and technology	29,567	11,962	55,727	22,287
Sales and marketing	88,381	51,920	168,075	115,082
General and administrative	39,579	6,332	83,365	12,219
Depreciation and amortization	8,369	4,521	13,730	8,866
Total costs and operating expenses	176,986	81,559	342,415	171,297
Operating (loss) income	(351)	41,736	(5,349)	85,406
Other expense, net:
Other income, net	0	(16)	0	(21)
Interest income	(13)	(41)	(29)	(116)
Interest expense	5,906	6,795	11,811	15,433
Total other expense, net	5,893	6,738	11,782	15,296
(Loss) income before income taxes	(6,244)	34,998	(17,131)	70,110
Income tax benefit (expense)	37,305	(7,661)	49,860	(15,427)
Net income	31,061	27,337	32,729	54,683
Net income attributable to common stockholders
Basic	31,061	17,663	32,729	35,325
Diluted	$ 31,061	$ 17,842	$ 32,729	$ 35,674
Earnings per share:
Basic	$ 0.08	$ 0.08	$ 0.08	$ 0.15
Diluted	$ 0.07	$ 0.08	$ 0.08	$ 0.15
Weighted average shares used in computing earnings per share:
Basic	408,363	230,160	407,273	230,020
Diluted	428,867	236,890	429,228	236,557
Cost of Sales
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 181	$ 24	$ 302	$ 41
Research and Development Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	7,987	918	16,323	1,814
Selling and Marketing Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	5,262	608	10,520	1,478
General and Administrative Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 27,246	$ 571	$ 60,057	$ 998

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Stock	Class A and Class B Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance at Dec. 31, 2019	$ (1,087,582)	$ 737,009		$ 460	$ 8,788	$ (1,096,830)
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2019		126,046,000
Beginning balance at Dec. 31, 2019				229,750,000
Stock options exercised	692			$ 1	691
Stock options exercised, Shares				467,000
Stock-based compensation	2,501				2,501
Net income	27,346					27,346
Ending balance at Mar. 31, 2020	(1,057,043)	$ 737,009		$ 461	11,980	(1,069,484)
Redeemable convertible preferred stock, Ending balance, Shares at Mar. 31, 2020		126,046,000
Ending balance at Mar. 31, 2020				230,217,000
Beginning balance at Dec. 31, 2019	(1,087,582)	$ 737,009		$ 460	8,788	(1,096,830)
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2019		126,046,000
Beginning balance at Dec. 31, 2019				229,750,000
Net income	54,683
Ending balance at Jun. 30, 2020	(1,026,735)	$ 737,009		$ 462	14,950	(1,042,147)
Redeemable convertible preferred stock, Ending balance, Shares at Jun. 30, 2020		126,046,000
Ending balance at Jun. 30, 2020				230,439,000
Beginning balance at Dec. 31, 2019	(1,087,582)	$ 737,009		$ 460	8,788	(1,096,830)
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2019		126,046,000
Beginning balance at Dec. 31, 2019				229,750,000
Ending balance at Dec. 31, 2020	711,359		$ 39		2,101,773	(1,390,453)
Redeemable convertible preferred stock, Ending balance, Shares at Dec. 31, 2020		0
Redeemable convertible preferred stock, Ending balance at Dec. 31, 2020		$ 0
Ending balance at Dec. 31, 2020			391,660,000
Beginning balance at Mar. 31, 2020	(1,057,043)	$ 737,009		$ 461	11,980	(1,069,484)
Redeemable convertible preferred stock, Beginning balance, Shares at Mar. 31, 2020		126,046,000
Beginning balance at Mar. 31, 2020				230,217,000
Stock options exercised	531			$ 1	530
Stock options exercised, Shares				222,000
Stock-based compensation	2,440				2,440
Net income	27,337					27,337
Ending balance at Jun. 30, 2020	(1,026,735)	$ 737,009		$ 462	14,950	(1,042,147)
Redeemable convertible preferred stock, Ending balance, Shares at Jun. 30, 2020		126,046,000
Ending balance at Jun. 30, 2020				230,439,000
Beginning balance at Dec. 31, 2020	711,359		$ 39		2,101,773	(1,390,453)
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2020		0
Beginning balance at Dec. 31, 2020			391,660,000
Stock options exercised	2,680		$ 0		2,680
Stock options exercised, Shares			513,000
Stock-based compensation	48,254				48,254
Vesting of restricted stock units	0		$ 0		0	0
Vesting of restricted stock awards, Shares			608,000
Common stock withheld for tax obligations and net settlement	(14,902)		$ 0		(14,902)	0
Common stock withheld for tax obligations and net settlement, Shares			(324,000)
Net income	1,668					1,668
Ending balance at Mar. 31, 2021	749,059		$ 39		2,137,805	(1,388,785)
Redeemable convertible preferred stock, Ending balance, Shares at Mar. 31, 2021		0
Redeemable convertible preferred stock, Ending balance at Mar. 31, 2021		$ 0
Ending balance at Mar. 31, 2021			392,457,000
Beginning balance at Dec. 31, 2020	711,359		$ 39		2,101,773	(1,390,453)
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2020		0
Redeemable convertible preferred stock, Beginning balance at Dec. 31, 2020		$ 0
Beginning balance at Dec. 31, 2020			391,660,000
Net income	32,729
Ending balance at Jun. 30, 2021	824,394	$ 0	$ 39		2,182,079	1,357,724
Redeemable convertible preferred stock, Ending balance, Shares at Jun. 30, 2021		0
Ending balance at Jun. 30, 2021			395,393,000
Beginning balance at Mar. 31, 2021	749,059		$ 39		2,137,805	(1,388,785)
Redeemable convertible preferred stock, Beginning balance, Shares at Mar. 31, 2021		0
Redeemable convertible preferred stock, Beginning balance at Mar. 31, 2021		$ 0
Beginning balance at Mar. 31, 2021			392,457,000
Stock options exercised	13,291				13,291
Stock options exercised, Shares			2,609,000
Stock-based compensation	42,366				42,366
Vesting of restricted stock awards, Shares			631,000
Common stock withheld for tax obligations and net settlement	(11,383)				(11,383)
Common stock withheld for tax obligations and net settlement, Shares			(304,000)
Net income	31,061					31,061
Ending balance at Jun. 30, 2021	$ 824,394	$ 0	$ 39		$ 2,182,079	$ 1,357,724
Redeemable convertible preferred stock, Ending balance, Shares at Jun. 30, 2021		0
Ending balance at Jun. 30, 2021			395,393,000

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net income	$ 32,729	$ 54,683
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	13,730	8,866
Amortization of debt issuance costs	1,727	1,596
Non-cash operating lease expense	1,791	2,232
Stock-based compensation	87,202	4,331
Deferred income taxes	(364)	2,292
Loss on abandonment of operating lease assets	780	0
Changes in operating assets and liabilities, net of effects of business acquisitions
Accounts receivable	(12,873)	(10,653)
Prepaid expenses and other assets	(47,241)	(3,952)
Accounts payable	4,917	753
Accrued expenses and other current liabilities	(1,897)	23,164
Operating lease liabilities	(590)	(224)
Other liabilities	500	737
Net cash provided by operating activities	80,411	83,825
Cash flows from investing activities
Purchase of property and equipment	(3,058)	(1,779)
Acquisitions, net cash acquired	(125,728)	0
Capitalized software	(13,630)	(6,540)
Net cash used in investing activities	(142,416)	(8,319)
Cash flows from financing activities
Proceeds from long-term debt	0	28,000
Payments on long-term debt	(3,515)	(3,515)
Payment for contingent consideration	(832)	0
Payments of debt issuance costs	0	(1,306)
Proceeds from exercise of stock options	15,481	1,223
Proceeds from early exercise of stock options	0	667
Employee taxes paid related to net share settlement of equity awards	(26,017)	0
Net cash (used in) provided by financing activities	(14,883)	25,069
Net change in cash, cash equivalents and restricted cash	(76,888)	100,575
Cash, cash equivalents and restricted cash
Beginning of period	971,591	26,050
End of period	894,703	126,625
Non cash investing and financing activities
Offering costs included in account payable and accrued expenses and other current liabilities	0	736
Right-of-use assets obtained in exchange for new operating lease liabilities	471	0
Stock-based compensation included in capitalized software development costs	3,418	610
Capitalized software development costs in accounts payable and accrued expenses and other current liabilities	828	269
Purchase of property and equipment included in accounts payable and accrued expenses and other current liabilities	0	2,125
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	894,703	126,625
Restricted cash	0	0
Total cash, cash equivalents and restricted cash	$ 894,703	$ 126,625

Description of Business

6 Months Ended

Jun. 30, 2021

Description Of Business [Abstract]

Description of Business

1. Description of Business

GoodRx Holdings, Inc. was incorporated in September 2015. On October 7, 2015, GoodRx Holdings, Inc. acquired 100% of the outstanding shares of GoodRx, Inc. (“GoodRx”). GoodRx, a Delaware corporation, was initially formed in September 2011.

GoodRx Holdings, Inc. and its subsidiaries (the “Company”) offer information and tools to help consumers compare prices and save on their prescription drug purchases. The Company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through GoodRx codes that can be used to save money on prescriptions across the United States (the “prescription offering”). The services are free to consumers and the Company primarily earns revenue from its core business from pharmacy benefit managers (“PBMs”) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. The Company also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions and telehealth services.

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information. Certain information and disclosures normally included in annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2020 and the related notes, which are included in the Company's Annual Report on Form 10-K filed with the SEC on March 12, 2021. The December 31, 2020 condensed consolidated balance sheet was derived from the Company’s audited consolidated financial statements as of that date. The Company’s condensed consolidated financial statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The Company’s significant accounting policies are discussed in “Note 2. Summary of Significant Accounting Policies” in the notes to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. There have been no material changes in accounting policies during the six months ended June 30, 2021 from those disclosed in the annual consolidated financial statements for the year ended December 31, 2020 and the related notes. During the three and six months ended June 30, 2021 and 2020, other than net income, the Company did not have any other elements of comprehensive income or loss. The operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the results expected for the full year ending December 31, 2021. Principles of Consolidation The condensed consolidated financial statements include the accounts of GoodRx Holdings, Inc., its wholly owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany balances and transactions have been eliminated in consolidation. Results of businesses acquired are included in the Company’s condensed consolidated financial statements from their respective dates of acquisition. Consolidation of VIEs GoodRx Care, LLC (formerly known as HeyDoctor), a wholly owned subsidiary of the Company, provides management and other services to professional service corporations (“PSCs”), which are owned by medical professionals in accordance with certain state laws that restrict the corporate practice of medicine and require medical practitioners to own such entities. The Company determined that the PSCs are VIEs. The Company also determined that it is able to direct the activities of the PSCs that most significantly impact their economic performance and it funds and absorbs all losses of these VIEs resulting in the Company being the primary beneficiary of the PSCs. Accordingly, the Company consolidates the VIEs. Revenue of the VIEs were approximately 2% of the Company’s revenue for each of the three and six months ended June 30, 2021 and 2020, respectively. The net results of operations of the VIEs for the three and six months ended June 30, 2021 and 2020 were not material. The VIEs’ total assets and liabilities were each approximately 1% of the Company’s total assets and liabilities at June 30, 2021 and December 31, 2020, respectively. Segment Reporting and Geographic Information Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker manages the Company on the basis of one operating segment. During the three and six months ended June 30, 2021 and 2020, all of the Company’s revenue was from customers located in the United States. In addition, at June 30, 2021 and December 31, 2020, all of the Company’s right-of-use assets and property and equipment was in the United States. Use of Estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements, including the accompanying notes. The Company bases its estimates on historical factors, current circumstances, and the experience and judgment of management. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates. Significant estimates reflected in the condensed consolidated financial statements include revenue recognition, valuation of intangible assets and assumptions used for purposes of determining stock-based compensation. Certain Risks and Concentrations Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains cash deposits with multiple financial institutions in the United States which, at times, may exceed federally insured limits. Cash may be withdrawn or redeemed on demand. The Company believes that the financial institutions that hold its cash are financially sound and, accordingly, minimal credit risk exists with respect to these balances. The Company has not experienced any losses in such accounts. The Company extends credit to its customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally does not obtain or require collateral. For the three months ended June 30, 2021, three customers accounted for approximately 13%, 11% and 10% of the Company’s revenue, respectively. For the six months ended June 30, 2021, three customers accounted for approximately 13%, 12% and 10% of the Company’s revenue, respectively. For the three months ended June 30, 2020, three customers accounted for approximately 17%, 17% and 11% of the Company's revenue, respectively. For the six months ended June 30, 2020, three customers accounted for approximately 18%, 18% and 12% of the Company's revenue, respectively. At June 30, 2021, no customers accounted for more than 10% of the Company’s accounts receivable balance. At December 31, 2020, one customer accounted for 12% of the Company’s accounts receivable balance. In March 2020, the World Health Organization declared the outbreak of the novel coronavirus disease (“COVID–19”) a pandemic. The Company’s prescription offering initially experienced a decline in activity as many consumers avoided visiting healthcare professionals and pharmacies in-person, though beginning in the second half of 2020 activity in the Company’s prescription offering improved. The Company’s prescription offering sequentially increased beginning in the third quarter of 2020 through the second quarter of 2021 as consumers partially resumed their interaction with the healthcare system. In addition, the Company has experienced a significant increase in demand for its telehealth offerings. The full extent to which the outbreak of COVID-19 will impact the Company’s business, results of operations and financial condition is still unknown and will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the pandemic, the actions to contain the virus or treat its impact, mutations of the virus, availability and adoption of effective vaccines and how quickly and to what extent normal economic and operating conditions can resume. In light of the currently unknown ultimate duration and severity of COVID-19, the Company faces a greater degree of uncertainty than normal in making the judgments and estimates needed to apply significant accounting policies. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s carrying value of goodwill and other long-lived assets, valuation of intangible assets acquired in business combinations, incentive-based compensation and income taxes. As of the date of these condensed consolidated financial statements, management is not aware of any specific event or circumstance that would require an update to estimates or judgments or a revision to the carrying value of assets or liabilities. However, these estimates and judgments may change as new events occur and additional information is obtained, which may result in changes being recognized in the Company’s condensed consolidated financial statements or annual consolidated financial statements in future periods. Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consist primarily of U.S. treasury securities money market funds held with an investment bank and cash on deposit. Cash equivalents, consisting of money market funds, of $852.5 million and $932.5 million at June 30, 2021 and December 31, 2020, respectively, were classified as Level 1 of the fair value hierarchy and valued using quoted market prices in active markets. Restricted cash as of December 31, 2020 represented cash held in an escrow pursuant to terms of the Scriptcycle, LLC business combination relating to contingent consideration, see "Note 3. Business Combinations – Scriptcycle, LLC.” Recent Accounting Pronouncements As an “emerging growth company”, the Jumpstart Our Business Startups Act, or the JOBS Act, allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use the adoption dates applicable to private companies. As a result, the Company’s consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies. Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. ASU 2018-15 requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud-computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. This guidance may be applied retrospectively or prospectively and is effective for fiscal years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. On January 1, 2021, the Company adopted ASU 2018-15 prospectively and cloud computing implementation costs incurred on or after January 1, 2021 are included in other assets in the consolidated balance sheet and are presented within operating cash flows. As of June 30, 2021, capitalized implementation costs for cloud computing arrangements were not material. In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to the Related Party Guidance for Variable Interest Entities. ASU 2018-17 changes how entities evaluate decision-making fees under the variable interest entity guidance. To determine whether decision-making fees represent a variable interest, an entity considers indirect interests held through related parties under common control on a proportional basis, rather than in their entirety. This guidance is effective for fiscal years, beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021, with early adoption permitted. All entities are required to apply the amendments in this ASU retrospectively with a cumulative-effect adjustment to retained earnings or accumulated deficit at the beginning of the earliest period presented. The Company adopted this guidance on January 1, 2021, and the adoption did not have any impact to the Company’s consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The objective of the guidance is to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and to provide more consistent application to improve the comparability of financial statements. The guidance is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The Company early adopted this guidance on January 1, 2021, and the adoption did not have a material impact to the Company’s consolidated financial statements. Recently Issued Accounting Pronouncements - Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, to require the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The ASU also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) (SEC Update), which amends the language in Subtopic 326-20 and addresses questions primarily regarding documentation and company policies. The guidance in ASU 2016-13 and ASU 2020-02 related to credit losses is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting. The ASU applies only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this ASU were effective upon issuance and may be applied through December 31, 2022. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.

Business Combination

6 Months Ended

Jun. 30, 2021

Business Combinations [Abstract]

Business Combination

3. Business Combinations

RxSaver, Inc.

On April 30, 2021, the Company acquired all of the outstanding equity interests of RxSaver, Inc. (“RxSaver”). Similar to the Company’s prescription offering business, RxSaver operates a price comparison platform to provide discount offerings through partnerships with PBMs. The acquisition expands the Company’s business capabilities and consumer reach, particularly with respect to its prescription offering. The aggregate purchase consideration was $50.7 million in cash. The purchase consideration is subject to net working capital and other closing adjustments.

Goodwill associated with this acquisition totaled $25.9 million and primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce. The acquisition was considered an acquisition of assets for tax purposes and, accordingly, goodwill is deductible for tax purposes. Identifiable intangible assets related to this acquisition totaled $25.2 million, of which $20.7 million was attributable to a customer related intangible asset, with an estimated useful life of 13 years; and $4.5 million was attributable to developed technology and a tradename with estimated useful lives ranging from 1 to 3 years. In addition, the Company acquired tangible assets of $3.6 million, principally comprised of accounts receivable, and assumed liabilities of $4.0 million.

Unaudited supplemental pro forma financial information for the RxSaver acquisition has not been presented because the effects are not material to the Company’s condensed consolidated financial statements.

The purchase accounting for the RxSaver acquisition remains incomplete with respect to acquired tangible and intangible assets and liabilities assumed as management continues to gather and evaluate information about circumstances that existed as of the acquisition date. Measurement period adjustments, if any, will be recognized in the reporting period in which the adjustment amounts are determined within twelve months from the acquisition date.

HealthiNation Inc.

On April 16, 2021, the Company acquired all of the outstanding equity interests of HealthiNation Inc. (“HealthiNation”). HealthiNation is a leading provider of engaging and informative health video content across all main categories of healthy living. The acquisition allows the Company to supplement and expand the services currently available under its existing pharma manufacturer solutions platform. The aggregate purchase consideration was $76.6 million in cash. The purchase consideration is subject to net working capital and other closing adjustments.

Goodwill associated with this acquisition totaled $33.2 million and primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce. The acquisition was considered a stock acquisition for tax purposes and, accordingly, goodwill is not deductible for tax purposes. Identifiable intangible assets related to this acquisition totaled $40.0 million, of which $28.0 million was attributable to a customer related intangible asset, with an estimated useful life of 11 years; $9.5 million was attributable to a content library with an estimated useful life of 3 years; $1.9 million was attributable to an order backlog, with an estimated useful life of 1 year; and $0.6 million was attributable to developed technology and a tradename with estimated useful lives of 1 year. In addition, the Company acquired tangible assets of $5.0 million, principally comprised of acquired cash and accounts receivable, and assumed liabilities of $1.6 million.

Unaudited supplemental pro forma financial information for the HealthiNation acquisition has not been presented because the effects are not material to the Company’s condensed consolidated financial statements.

The purchase accounting for the HealthiNation acquisition remains incomplete with respect to acquired tangible and intangible assets and liabilities assumed as management continues to gather and evaluate information about circumstances that existed as of the acquisition date. Measurement period adjustments, if any, will be recognized in the reporting period in which the adjustment amounts are determined within twelve months from the acquisition date.

Scriptcycle, LLC

On August 31, 2020, the Company acquired all of the equity interests of Scriptcycle, LLC (“Scriptcycle”). Scriptcycle specializes in managing prescription programs and primarily partners with regional retail pharmacy chains to provide discount offerings. The purpose of the acquisition was to help expand the Company’s business capabilities, particularly with respect to its prescription offering. The aggregate purchase consideration was $58.3 million, including the estimated fair value of contingent consideration of $0.8 million. The purchase consideration was subject to working capital and other closing adjustments. The maximum amount of contingent consideration payable was $2.9 million subject to the achievement of certain revenue thresholds through January 2021.

As of December 31, 2020, the fair value of the contingent consideration was $2.9 million, which represents the maximum amount of contingent consideration payable, based upon the Company’s assessment of the revenue thresholds that were achieved. The $2.9 million contingent consideration was paid in full during the three months ended June 30, 2021.

Goodwill associated with this acquisition totaled $24.9 million and primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce. The acquisition was considered an acquisition of assets for tax purposes and, accordingly, goodwill was deductible for tax purposes. Identifiable intangible assets related to this acquisition totaled $28.3 million, of which $25.3 million was attributable to a customer related intangible asset, with an estimated useful life of 11 years and $3.0 million was attributable to developed technology and a tradename with useful lives ranging from 1 to 9 years. In addition, the Company acquired current assets of $5.9 million and assumed liabilities of $1.1 million.

Unaudited supplemental pro forma financial information for the Scriptcycle acquisition has not been presented because the effects are not material to the Company’s condensed consolidated financial statements.

Prepaid Expenses and Other Current Assets

6 Months Ended

Jun. 30, 2021

Prepaid Expense And Other Assets Current [Abstract]

Prepaid Expenses and Other Current Assets

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:


(in thousands)	June 30, 2021		December 31, 2020
Income taxes receivable	$	79,797	$	28,564
Prepaid expenses		14,246		17,484
Total prepaid expenses and other current assets	$	94,043	$	46,048

Accrued Expenses and Other Current Liabilities

6 Months Ended

Jun. 30, 2021

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

5. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:


(in thousands)	June 30, 2021		December 31, 2020
Accrued bonus and other payroll related	$	13,500	$	13,607
Accrued marketing		8,773		10,045
Deferred revenue		8,899		6,852
Other accrued expenses		2,587		7,188
Total accrued expenses and other current liabilities	$	33,759	$	37,692

The Company expects substantially all of the deferred revenue at June 30, 2021 will be recognized as revenue within the next twelve months. Of the $6.9 million deferred revenue included in the condensed consolidated balance sheet at December 31, 2020, $1.4 million and $5.7 million was recognized as revenue during the three and six months ended June 30, 2021, respectively. Revenue recognized during the three and six months ended June 30, 2020 of $0.9 million and $2.8 million, respectively, was included as deferred revenue at December 31, 2019.

Income Taxes

6 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes

6. Income Taxes

The Company calculates income taxes in interim periods by applying an estimated annual effective income tax rate to (loss) income before income taxes and by calculating the tax effect of discrete items recognized during the period.

The Company's estimated annual effective income tax rate is based on its estimated full year income or loss and the related income taxes for each jurisdiction in which the Company operates. This rate can be affected by estimates of full year pretax income or loss and permanent differences. The Company’s interim and estimated annual effective income tax rates differ from the U.S. Federal statutory rate of 21.0% primarily due to effects of non-deductible officers’ stock-based compensation expense, state income taxes, and benefits from research and development tax credits. In addition, the Company's effective income tax rate includes recognized excess tax benefits from its equity awards as a discrete item.

As of December 31, 2020, the Company had unrecognized tax benefits of $7.4 million. There were no significant changes to the Company’s unrecognized tax benefits during the three and six months ended June 30, 2021, and the Company does not expect to have any significant changes to unrecognized tax benefits through the end of 2021.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Debt

6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Debt

7. Debt

The Company has a term loan with an original amount of $700.0 million (the “First Lien Term Loan Facility”) under its first lien credit agreement (the “First Lien Credit Agreement”) obtained through its wholly owned subsidiary GoodRx as borrower and collateralized by all of the assets of the Company and 100% of the equity of GoodRx. The First Lien Term Loan Facility requires quarterly payments through September 2025, with any unpaid principal and interest due upon maturity on October 10, 2025, and bears interest at a rate per annum equal to the LIBO Screen Rate plus a variable margin based on the Company’s most recently determined Net Leverage Ratio (as defined in the First Lien Credit Agreement), ranging from 2.75% to 3.00%. The effective interest rate on the First Lien Term Facility for the three months ended June 30, 2021 and 2020 was 3.39% and 3.83%, respectively. The effective interest rate on the First Lien Term Loan Facility for the six months ended June 30, 2021 and 2020 was 3.39% and 4.33%, respectively.

The Company also has a line of credit with a maximum amount of $100.0 million (the “Revolving Credit Facility”) associated with the First Lien Credit Agreement. The Revolving Credit Facility matures on October 11, 2024 and bears interest at a rate equal to the LIBO Screen Rate plus a variable margin based on the Company’s most recently determined Net Leverage Ratio (as defined in the First Lien Credit Agreement), ranging from 2.50 to 3.00% on used amounts and 0.25 to 0.50% on unused amounts. There were no borrowings outstanding under the Revolving Credit Facility as of June 30, 2021 and December 31, 2020. There were outstanding letters of credit issued against the Revolving Credit Facility for $9.1 million as of June 30, 2021 and December 31, 2020, which reduces the Company’s available borrowings under the Revolving Credit Facility.

The Company’s debt consisted of the following:


(in thousands)	June 30, 2021			December 31, 2020
Principal balance under First Lien Term Loan Facility	$	677,611		$	681,126
Less: Unamortized debt issuance costs and discounts		(12,705	)		(14,209	)
	$	664,906		$	666,917

As of June 30, 2021, the Company is subject to a financial covenant requiring maintenance of a Net Leverage Ratio not to exceed 8.2 to 1.0 and other nonfinancial covenants under the First Lien Credit Agreement. Additionally, GoodRx is restricted from making dividend payments, loans or advances to the Company. At June 30, 2021, the Company was in compliance with its covenants.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

8. Commitments and Contingencies

Aside from the below, as of June 30, 2021, there were no material changes to the Company’s commitments and contingencies as disclosed in the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Purchase Commitments

The Company entered into a commercial agreement with a third-party during the quarter ended March 31, 2021, pursuant to which the Company committed to spend an aggregate of at least $3.0 million by the end of the fiscal year ending December 31, 2021 on certain advertising services. As of June 30, 2021, the remaining commitment was $1.2 million.

Leases

On May 27, 2021, the Company entered into a non-cancelable lease agreement with a third-party to lease additional office space that is adjacent to and expands its existing corporate headquarters in Santa Monica, California. The lease commences beginning in the year 2022 and expires in the year 2033 with minimum lease payments expected to total approximately $41.4 million over the term of the lease.

Legal Contingencies

On December 18, 2020, R. Brian Terenzini, individually and on behalf of all others similarly situated, filed a class action lawsuit against the Company and certain of its executive officers in the United States District Court for the Central District of California (Case No. 2:20-cv-11444). On January 8, 2021, Bryan Kearney, individually and on behalf of all others similarly situated, also filed a class action lawsuit against the Company and certain of its executive officers in the United States District Court for the Central District of California (Case No. 2:21-cv-00175). The plaintiffs seek compensatory damages as well as interest, fees and costs. The complaints allege violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and assert that the Company failed to disclose to investors that Amazon.com, Inc. was developing its own mobile and online prescription medication ordering and fulfillment service that would compete directly with the Company. According to the complaints, when Amazon announced its competitor service, the Company’s stock price fell, causing investor losses. Lead plaintiff applications were submitted February 16, 2021, and on April 8, 2021, the court consolidated the two lawsuits under the caption In re GoodRx Holdings, Inc.(Case No. 2:20-cv-11444) and appointed Betty Kalmanson, Lawrence Kalmanson, Shawn Kalmanson, and Janice Kasbaum as Lead Plaintiffs. On June 7, 2021, Lead Plaintiffs filed a consolidated complaint containing substantially similar factual allegations as the prior complaints, but adding claims under Section 11 of the Securities Act of 1933. The Company filed a motion to dismiss the consolidated case on August 6, 2021. The Company believes it has meritorious defenses to the claims of the plaintiffs and members of the class and intends to defend itself vigorously. This litigation is at preliminary stages, and the outcome of any complex legal proceeding is inherently unpredictable and subject to significant uncertainties. Based upon information presently known to management, the Company has not accrued a loss for this matter as a loss is not probable and reasonably estimable. While it is possible a loss may have been incurred, the Company is unable to estimate a loss or range of loss in this matter.

On April 29, 2021 and May 5, 2021, Neesha Patel and Wayne Geist, respectively, each filed a derivative lawsuit purportedly on behalf of the Company against certain of its officers and directors in the United States District Court for the Central District of California (Case No. 2:21-cv-03671 and Case No. 2:21-cv-03829, respectively). The plaintiffs assert claims for breach of fiduciary duty and contribution under the Exchange Act. Neesha Patel asserts additional claims for

unjust enrichment and corporate waste. These claims are based on allegations substantially similar to those in the class action lawsuit described above. Plaintiffs are requesting declaratory relief, money damages, restitution, and certain governance reforms. Plaintiffs did not make a pre-suit demand on the Company’s board. The Company intends to seek dismissal of these cases, or a stay pending the outcome of the class action lawsuit. Any liability for the claims alleged is not currently probable and a loss or range of loss, if any, is not reasonably estimable.

The pending proceedings described above involve complex questions of fact and law and may require the expenditure of significant funds and the diversion of other resources to defend. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible.

In addition, during the normal course of business, the Company may become subject to, and is presently involved in, legal proceedings, claims and litigation. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. Accruals for loss contingencies are recorded when a loss is probable, and the amount of such loss can be reasonably estimated.

The Company does not believe that the disposition of matters that are pending or asserted will have a material effect on its consolidated financial statements.

Indemnification

The Company’s amended and restated bylaws provides that it will indemnify the Company’s directors and officers to the fullest extent permitted by the Delaware General Corporation Law. Certain of the Company’s officers and directors are also a party to indemnification agreements with the Company. Pursuant to the Company’s indemnification agreements and directors’ and officers’ liability insurance, certain of the Company’s officers and directors will be indemnified and insured against the cost of defense, settlement or payment of a judgment under certain circumstances. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is indeterminable. The Company has never paid a material claim, nor has the Company been involved in litigation, with respect to these indemnification arrangements. As of June 30, 2021 and December 31, 2020, the Company has not accrued a liability for these guarantees as, the likelihood of incurring a payment obligation, if any, in connection with these guarantees is not probable or reasonably estimable.

Revenue

6 Months Ended

Jun. 30, 2021

Revenue From Contract With Customer [Abstract]

Revenue

9. Revenue

Revenue consisted of the following:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2021		2020		2021		2020
Prescription transactions revenue	$	144,857	$	109,548	$	278,918	$	232,565
Subscription revenue (1)		14,316		6,358		26,323		11,998
Other revenue		17,462		7,389		31,825		12,140
Total revenue	$	176,635	$	123,295	$	337,066	$	256,703
(1) Represents revenue from the Company's Gold and Kroger Savings subscription offerings. Subscription revenue is disclosed separately from other revenue beginning in the second quarter of 2021. Prior period amounts have been recast to conform with the current period presentation.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Stock-Based Compensation

6 Months Ended

Jun. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

10. Stock-Based Compensation

Stock Options

A summary of the stock option activity is as follows:


						Weighted
				Weighted		Average
				Average		Remaining	Aggregate
				Exercise		Contractual	Intrinsic
(in thousands, except per share amounts and term information)	Shares			Price		Term	Value
Outstanding at December 31, 2020		21,528		$	6.22
Granted		—			—
Exercised		(513	)		5.23
Expired / Cancelled / Forfeited		(253	)		6.07
Outstanding at March 31, 2021		20,762		$	6.24	7.9 years	$	680,528
Granted		—			—
Exercised		(2,609	)		5.09
Expired / Cancelled / Forfeited		(222	)		7.71
Outstanding at June 30, 2021		17,931		$	6.39	7.7 years	$	531,079
Exercisable at June 30, 2021		8,756		$	4.36	6.8 years	$	277,143

There were no stock options granted during the three and six months ended June 30, 2021. The weighted-average grant date fair value per share of stock options granted for the three and six months ended June 30, 2020 was $3.17 and $3.04, respectively. The aggregate intrinsic value of options exercised for the three months ended June 30, 2021 and 2020 was $79.9 million and $1.0 million, respectively. The aggregate intrinsic value of options exercised for the six months ended June 30, 2021 and 2020 was $98.6 million and $2.4 million, respectively.

All options outstanding at June 30, 2021 are options to purchase shares of Class A common stock. The fair value of option awards issued with service or service and performance vesting conditions are estimated on the grant date using the Black-Scholes option pricing model. The Company does not have material stock options issued with market vesting conditions.

For the three months ended June 30, 2021 and 2020, the stock-based compensation expense related to stock options was $3.9 million and $1.7 million, respectively. For the six months ended June 30, 2021 and 2020, the stock-based compensation expense related to stock options was $8.1 million and $3.4 million, respectively. At June 30, 2021, there was $26.5 million of total unrecognized stock-based compensation cost related to stock options, which is expected to be recognized over a weighted average remaining service period of 2.5 years.

Restricted Stock Awards and Restricted Stock Units

A summary of the Restricted Stock Awards (“RSAs”) and Restricted Stock Unit (“RSUs”) activity is as follows:


	Restricted			Restricted Stock Units for Class A			Restricted Stock Units for Class B			Weighted Average
	Stock			Common			Common			Grant Date
(in thousands, except per share amounts)	Awards			Stock			Stock			Fair Value
Nonvested restricted stock awards or restricted stock units at December 31, 2020		1,409			2,790			7,698		$	26.74
Granted		—			647			—			44.12
Vested		—			(95	)		(513	)		29.12
Forfeited		—			(17	)		—			42.31
Nonvested restricted stock awards or restricted stock units at March 31, 2021		1,409			3,325			7,185		$	28.05
Granted		—			618			—			37.86
Vested		(470	)		(118	)		(513	)		18.68
Forfeited		—			(67	)		—			36.61
Nonvested restricted stock awards or restricted stock units at June 30, 2021		939			3,758			6,672		$	29.44

There were no RSUs granted or outstanding during the three and six months ended June 30, 2020.

Restricted Stock Awards

For the three months ended June 30, 2021 and 2020, total stock-based compensation expense related to RSAs was $0.5 million and $0.4 million, respectively. For the six months ended June 30, 2021 and 2020, total stock-based compensation expense related to RSAs was $1.0 million and $0.9 million, respectively. At June 30, 2021, there was $3.2 million of total unrecognized stock-based compensation cost related to these RSAs which is expected to be recognized over the remaining service period of 1.8 years. There were no RSAs granted subsequent to December 31, 2019.

Restricted Stock Units for Class A Common Stock

For the three and six months ended June 30, 2021, total stock-based compensation expense related to RSUs for Class A common stock was $12.3 million and $24.1 million, respectively. At June 30, 2021, there was $131.7 million of total unrecognized stock-based compensation cost related to these RSUs which is expected to be recognized over the weighted average remaining service period of 3.4 years.

Restricted Stock Units for Class B Common Stock

On September 11, 2020, the board of directors granted RSUs covering an aggregate of 24,633,066 shares of Class B common stock to the Company’s Co-Chief Executive Officers (the “Founders Awards”), subject to the completion of the Company’s initial public offering. Each of the Co-Chief Executive Officers received (i) 8,211,022 RSUs that vest based on the achievement of stock price goals ranging from $6.07 per share to $51.28 per share, subject to continued employment through the applicable vesting date (the “Performance-Vesting Founders Awards”) and (ii) 4,105,511 RSUs that vest and settle in equal quarterly installments over four years, subject to continued employment through the applicable vesting date (the “Time-Vesting Founders Awards”). The grant date fair value of these awards was $533.3 million. The Performance-Vesting Founders Awards vested during the fourth quarter of 2020 and will be settled in shares of common stock in October 2023 or, if earlier, upon a qualifying change in control event or to satisfy tax withholding requirements. The Time-Vesting Founders Awards are subject to vesting acceleration terms upon a qualifying change in control. All the stock price goals with respect to the Performance-Vesting Founders Awards were achieved as of October 22, 2020. As a result, all 16,422,044 Performance-Vesting Founders Awards vested during the year ended December 31, 2020. As of June 30, 2021, the Company has recognized a cumulative $427.0 million of stock-based compensation expense related to the Founders Awards, of which $107.2 million related to the Time-Vesting Founders Awards and $319.8 million related to the Performance-Vesting Founders Awards. During the three and six months ended June 30, 2021, the Company recognized stock-based compensation expense related to the Time-Vesting Founders Awards of $24.0 million and $54.0 million, respectively. At June 30, 2021, there was $106.3 million of total unrecognized stock-based compensation cost related to the Time-Vesting Founders Awards, which is expected to be recognized over the weighted average remaining service period of 1.9 years. The Company expects to recognize a total of $36.9 million in stock-based compensation expense related to the Time-Vesting Founders Awards in the second half of 2021.

As the Performance-Vesting Founders Awards vested in October 2020, the Company settled 0.7 million RSUs during the fourth quarter of 2020, sufficient to satisfy FICA tax withholding obligations due in the year of vesting. The remaining 15.7 million Performance-Vesting Founders Awards shares will not be issued until October 2023 or, if earlier, a change in control event, as defined in the RSU agreements governing the Founders Awards.

Basic and Diluted Earnings Per Share

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Basic and Diluted Earnings Per Share

11. Basic and Diluted Earnings Per Share

The computation of earnings per share for the three and six months ended June 30, 2021 and 2020 is as follows:


	Three Months Ended June 30,					Six Months Ended June 30,
(in thousands, except per share amounts)	2021		2020			2021		2020
Numerator:
Net income	$	31,061	$	27,337		$	32,729	$	54,683
Less: Undistributed earnings allocated to convertible preferred stock		—		(9,674	)		—		(19,358	)
Net income attributable to common stockholders - basic	$	31,061	$	17,663		$	32,729	$	35,325
Add: Undistributed earnings reallocated to holders of common stock		—		179			—	349
Net income attributable to common stockholders - diluted	$	31,061	$	17,842		$	32,729	$	35,674
Denominator:
Weighted average shares - basic		408,363		230,160			407,273		230,020
Dilutive impact of stock options, restricted stock awards and restricted stock units		20,504		6,730			21,955		6,537
Weighted average shares - diluted		428,867		236,890			429,228		236,557
Earnings per share:
Basic	$	0.08	$	0.08		$	0.08	$	0.15
Diluted	$	0.07	$	0.08		$	0.08	$	0.15

The following weighted average potentially dilutive shares were excluded from the computation of diluted earnings per share for the periods presented because including them would have been antidilutive:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2021		2020		2021		2020
Redeemable convertible preferred stock		—		126,046		—		126,046
Stock options, restricted stock awards and restricted stock units		3,277		11,556		1,904		11,309

Subsequent Events

6 Months Ended

Jun. 30, 2021

Subsequent Events [Abstract]

Subsequent Events

12. Subsequent Events

On July 7, 2021, the Company acquired substantially all of the assets of RxNXT LLC (“RxNXT”) for $14.5 million in cash, subject to customary closing adjustments. RxNXT is a prescription technology platform. The purpose of the acquisition is to help expand the Company’s business capabilities, particularly with respect to its prescription offering. The acquisition will be accounted for as a business combination under Accounting Standard Codification 805, Business Combinations, using the acquisition method of accounting, which among other things, requires the acquired assets and assumed liabilities be recorded at their fair values. The determination of the fair values of the acquired assets and assumed liabilities is incomplete due to the recent date of the acquisition. The results of operations of RxNXT will be included in the consolidated results of the Company beginning from the date of acquisition.

On July 21, 2021, the Company’s board of directors granted equity awards to certain employees comprised principally of RSUs for 0.5 million shares of Class A common stock, which will substantially vest over a four-year period. The Company estimates the grant date fair value of these RSUs is approximately $15.2 million, which will be recognized as stock-based compensation cost, net of forfeitures that occur, over approximately four years.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information. Certain information and disclosures normally included in annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2020 and the related notes, which are included in the Company's Annual Report on Form 10-K filed with the SEC on March 12, 2021. The December 31, 2020 condensed consolidated balance sheet was derived from the Company’s audited consolidated financial statements as of that date. The Company’s condensed consolidated financial statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The Company’s significant accounting policies are discussed in “Note 2. Summary of Significant Accounting Policies” in the notes to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. There have been no material changes in accounting policies during the six months ended June 30, 2021 from those disclosed in the annual consolidated financial statements for the year ended December 31, 2020 and the related notes. During the three and six months ended June 30, 2021 and 2020, other than net income, the Company did not have any other elements of comprehensive income or loss. The operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the results expected for the full year ending December 31, 2021.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of GoodRx Holdings, Inc., its wholly owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany balances and transactions have been eliminated in consolidation. Results of businesses acquired are included in the Company’s condensed consolidated financial statements from their respective dates of acquisition. Consolidation of VIEs GoodRx Care, LLC (formerly known as HeyDoctor), a wholly owned subsidiary of the Company, provides management and other services to professional service corporations (“PSCs”), which are owned by medical professionals in accordance with certain state laws that restrict the corporate practice of medicine and require medical practitioners to own such entities. The Company determined that the PSCs are VIEs. The Company also determined that it is able to direct the activities of the PSCs that most significantly impact their economic performance and it funds and absorbs all losses of these VIEs resulting in the Company being the primary beneficiary of the PSCs. Accordingly, the Company consolidates the VIEs. Revenue of the VIEs were approximately 2% of the Company’s revenue for each of the three and six months ended June 30, 2021 and 2020, respectively. The net results of operations of the VIEs for the three and six months ended June 30, 2021 and 2020 were not material. The VIEs’ total assets and liabilities were each approximately 1% of the Company’s total assets and liabilities at June 30, 2021 and December 31, 2020, respectively.
Segment Reporting and Geographic Information	Segment Reporting and Geographic Information Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker manages the Company on the basis of one operating segment. During the three and six months ended June 30, 2021 and 2020, all of the Company’s revenue was from customers located in the United States. In addition, at June 30, 2021 and December 31, 2020, all of the Company’s right-of-use assets and property and equipment was in the United States.
Use of Estimates	Use of Estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements, including the accompanying notes. The Company bases its estimates on historical factors, current circumstances, and the experience and judgment of management. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates. Significant estimates reflected in the condensed consolidated financial statements include revenue recognition, valuation of intangible assets and assumptions used for purposes of determining stock-based compensation.
Certain Risks and Concentrations	Certain Risks and Concentrations Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains cash deposits with multiple financial institutions in the United States which, at times, may exceed federally insured limits. Cash may be withdrawn or redeemed on demand. The Company believes that the financial institutions that hold its cash are financially sound and, accordingly, minimal credit risk exists with respect to these balances. The Company has not experienced any losses in such accounts. The Company extends credit to its customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally does not obtain or require collateral. For the three months ended June 30, 2021, three customers accounted for approximately 13%, 11% and 10% of the Company’s revenue, respectively. For the six months ended June 30, 2021, three customers accounted for approximately 13%, 12% and 10% of the Company’s revenue, respectively. For the three months ended June 30, 2020, three customers accounted for approximately 17%, 17% and 11% of the Company's revenue, respectively. For the six months ended June 30, 2020, three customers accounted for approximately 18%, 18% and 12% of the Company's revenue, respectively. At June 30, 2021, no customers accounted for more than 10% of the Company’s accounts receivable balance. At December 31, 2020, one customer accounted for 12% of the Company’s accounts receivable balance. In March 2020, the World Health Organization declared the outbreak of the novel coronavirus disease (“COVID–19”) a pandemic. The Company’s prescription offering initially experienced a decline in activity as many consumers avoided visiting healthcare professionals and pharmacies in-person, though beginning in the second half of 2020 activity in the Company’s prescription offering improved. The Company’s prescription offering sequentially increased beginning in the third quarter of 2020 through the second quarter of 2021 as consumers partially resumed their interaction with the healthcare system. In addition, the Company has experienced a significant increase in demand for its telehealth offerings. The full extent to which the outbreak of COVID-19 will impact the Company’s business, results of operations and financial condition is still unknown and will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the pandemic, the actions to contain the virus or treat its impact, mutations of the virus, availability and adoption of effective vaccines and how quickly and to what extent normal economic and operating conditions can resume. In light of the currently unknown ultimate duration and severity of COVID-19, the Company faces a greater degree of uncertainty than normal in making the judgments and estimates needed to apply significant accounting policies. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s carrying value of goodwill and other long-lived assets, valuation of intangible assets acquired in business combinations, incentive-based compensation and income taxes. As of the date of these condensed consolidated financial statements, management is not aware of any specific event or circumstance that would require an update to estimates or judgments or a revision to the carrying value of assets or liabilities. However, these estimates and judgments may change as new events occur and additional information is obtained, which may result in changes being recognized in the Company’s condensed consolidated financial statements or annual consolidated financial statements in future periods.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consist primarily of U.S. treasury securities money market funds held with an investment bank and cash on deposit. Cash equivalents, consisting of money market funds, of $852.5 million and $932.5 million at June 30, 2021 and December 31, 2020, respectively, were classified as Level 1 of the fair value hierarchy and valued using quoted market prices in active markets. Restricted cash as of December 31, 2020 represented cash held in an escrow pursuant to terms of the Scriptcycle, LLC business combination relating to contingent consideration, see "Note 3. Business Combinations – Scriptcycle, LLC.”
Recent Accounting Pronouncements	Recent Accounting Pronouncements As an “emerging growth company”, the Jumpstart Our Business Startups Act, or the JOBS Act, allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use the adoption dates applicable to private companies. As a result, the Company’s consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies. Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. ASU 2018-15 requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud-computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. This guidance may be applied retrospectively or prospectively and is effective for fiscal years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. On January 1, 2021, the Company adopted ASU 2018-15 prospectively and cloud computing implementation costs incurred on or after January 1, 2021 are included in other assets in the consolidated balance sheet and are presented within operating cash flows. As of June 30, 2021, capitalized implementation costs for cloud computing arrangements were not material. In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to the Related Party Guidance for Variable Interest Entities. ASU 2018-17 changes how entities evaluate decision-making fees under the variable interest entity guidance. To determine whether decision-making fees represent a variable interest, an entity considers indirect interests held through related parties under common control on a proportional basis, rather than in their entirety. This guidance is effective for fiscal years, beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021, with early adoption permitted. All entities are required to apply the amendments in this ASU retrospectively with a cumulative-effect adjustment to retained earnings or accumulated deficit at the beginning of the earliest period presented. The Company adopted this guidance on January 1, 2021, and the adoption did not have any impact to the Company’s consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The objective of the guidance is to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and to provide more consistent application to improve the comparability of financial statements. The guidance is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The Company early adopted this guidance on January 1, 2021, and the adoption did not have a material impact to the Company’s consolidated financial statements. Recently Issued Accounting Pronouncements - Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, to require the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The ASU also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) (SEC Update), which amends the language in Subtopic 326-20 and addresses questions primarily regarding documentation and company policies. The guidance in ASU 2016-13 and ASU 2020-02 related to credit losses is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting. The ASU applies only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this ASU were effective upon issuance and may be applied through December 31, 2022. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.

- Definition

Disclosure of accounting policy for segment reporting.

+ References + Details

Prepaid Expenses and Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2021

Prepaid Expense And Other Assets Current [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:


(in thousands)	June 30, 2021		December 31, 2020
Income taxes receivable	$	79,797	$	28,564
Prepaid expenses		14,246		17,484
Total prepaid expenses and other current assets	$	94,043	$	46,048

Accrued Expenses and Other Current Liabilities (Tables)

6 Months Ended

Jun. 30, 2021

Payables And Accruals [Abstract]

Summary of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:


(in thousands)	June 30, 2021		December 31, 2020
Accrued bonus and other payroll related	$	13,500	$	13,607
Accrued marketing		8,773		10,045
Deferred revenue		8,899		6,852
Other accrued expenses		2,587		7,188
Total accrued expenses and other current liabilities	$	33,759	$	37,692

Debt (Tables)

6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Schedule of Debt

The Company’s debt consisted of the following:


(in thousands)	June 30, 2021			December 31, 2020
Principal balance under First Lien Term Loan Facility	$	677,611		$	681,126
Less: Unamortized debt issuance costs and discounts		(12,705	)		(14,209	)
	$	664,906		$	666,917

Revenue (Tables)

6 Months Ended

Jun. 30, 2021

Revenue From Contract With Customer [Abstract]

Summary of Revenue

Revenue consisted of the following:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2021		2020		2021		2020
Prescription transactions revenue	$	144,857	$	109,548	$	278,918	$	232,565
Subscription revenue (1)		14,316		6,358		26,323		11,998
Other revenue		17,462		7,389		31,825		12,140
Total revenue	$	176,635	$	123,295	$	337,066	$	256,703
(1) Represents revenue from the Company's Gold and Kroger Savings subscription offerings. Subscription revenue is disclosed separately from other revenue beginning in the second quarter of 2021. Prior period amounts have been recast to conform with the current period presentation.

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2021

Summary of Stock Option Activity

A summary of the stock option activity is as follows:


						Weighted
				Weighted		Average
				Average		Remaining	Aggregate
				Exercise		Contractual	Intrinsic
(in thousands, except per share amounts and term information)	Shares			Price		Term	Value
Outstanding at December 31, 2020		21,528		$	6.22
Granted		—			—
Exercised		(513	)		5.23
Expired / Cancelled / Forfeited		(253	)		6.07
Outstanding at March 31, 2021		20,762		$	6.24	7.9 years	$	680,528
Granted		—			—
Exercised		(2,609	)		5.09
Expired / Cancelled / Forfeited		(222	)		7.71
Outstanding at June 30, 2021		17,931		$	6.39	7.7 years	$	531,079
Exercisable at June 30, 2021		8,756		$	4.36	6.8 years	$	277,143

Restricted Stock

Summary of Restricted Stock Activity

A summary of the Restricted Stock Awards (“RSAs”) and Restricted Stock Unit (“RSUs”) activity is as follows:


	Restricted			Restricted Stock Units for Class A			Restricted Stock Units for Class B			Weighted Average
	Stock			Common			Common			Grant Date
(in thousands, except per share amounts)	Awards			Stock			Stock			Fair Value
Nonvested restricted stock awards or restricted stock units at December 31, 2020		1,409			2,790			7,698		$	26.74
Granted		—			647			—			44.12
Vested		—			(95	)		(513	)		29.12
Forfeited		—			(17	)		—			42.31
Nonvested restricted stock awards or restricted stock units at March 31, 2021		1,409			3,325			7,185		$	28.05
Granted		—			618			—			37.86
Vested		(470	)		(118	)		(513	)		18.68
Forfeited		—			(67	)		—			36.61
Nonvested restricted stock awards or restricted stock units at June 30, 2021		939			3,758			6,672		$	29.44

Basic and Diluted Earnings Per Share (Tables)

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Schedule Computation of Earnings Per Share

The computation of earnings per share for the three and six months ended June 30, 2021 and 2020 is as follows:


	Three Months Ended June 30,					Six Months Ended June 30,
(in thousands, except per share amounts)	2021		2020			2021		2020
Numerator:
Net income	$	31,061	$	27,337		$	32,729	$	54,683
Less: Undistributed earnings allocated to convertible preferred stock		—		(9,674	)		—		(19,358	)
Net income attributable to common stockholders - basic	$	31,061	$	17,663		$	32,729	$	35,325
Add: Undistributed earnings reallocated to holders of common stock		—		179			—	349
Net income attributable to common stockholders - diluted	$	31,061	$	17,842		$	32,729	$	35,674
Denominator:
Weighted average shares - basic		408,363		230,160			407,273		230,020
Dilutive impact of stock options, restricted stock awards and restricted stock units		20,504		6,730			21,955		6,537
Weighted average shares - diluted		428,867		236,890			429,228		236,557
Earnings per share:
Basic	$	0.08	$	0.08		$	0.08	$	0.15
Diluted	$	0.07	$	0.08		$	0.08	$	0.15

Weighted-Average Potentially Dilutive Shares Were Excluded From Computation of Diluted Earnings Per Share


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2021		2020		2021		2020
Redeemable convertible preferred stock		—		126,046		—		126,046
Stock options, restricted stock awards and restricted stock units		3,277		11,556		1,904		11,309

Description of Business - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021	Oct. 07, 2015
Description Of Business [Line Items]
Entity incorporation month and year	2015-09
GoodRx, Inc.
Description Of Business [Line Items]
Percentage of outstanding shares acquired		100.00%

Summary of Significant Accounting Policies - Additional Information (Details) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021 USD ($) Customer	Jun. 30, 2020 Customer	Jun. 30, 2021 USD ($) Customer Segment	Jun. 30, 2020 Customer	Dec. 31, 2020 USD ($) Customer
Accounting Policies [Line Items]
Variable interest entity's percentage of total revenue	2.00%	2.00%	2.00%	2.00%
Variable interest entity's percentage of total assets and liabilities			1.00%		1.00%
Number of operating segment \| Segment			1
Accounting Standards Update 2018-15
Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true		true
Change in accounting principle accounting standards update adoption date	Jan. 01, 2021		Jan. 01, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true		true
Accounting Standards Update 2018-17
Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true		true
Change in accounting principle accounting standards update adoption date	Jan. 01, 2021		Jan. 01, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true		true
Accounting Standards Update 2019-12
Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true		true
Change in accounting principle, accounting standards update, early adoption [true false]	true		true
Change in accounting principle accounting standards update adoption date	Jan. 01, 2021		Jan. 01, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true		true
Money Market Funds \| Fair Value, Inputs, Level 1
Accounting Policies [Line Items]
Cash equivalents, fair value disclosure \| $	$ 852.5		$ 852.5		$ 932.5
Customer Concentration Risk \| Revenue From Customer
Accounting Policies [Line Items]
Number of customers	3	3	3	3
Customer Concentration Risk \| Revenue From Customer \| Customer One
Accounting Policies [Line Items]
Concentration risk percentage	13.00%	17.00%	13.00%	18.00%
Customer Concentration Risk \| Revenue From Customer \| Customer Two
Accounting Policies [Line Items]
Concentration risk percentage	11.00%	17.00%	12.00%	18.00%
Customer Concentration Risk \| Revenue From Customer \| Customer Three
Accounting Policies [Line Items]
Concentration risk percentage	10.00%	11.00%	10.00%	12.00%
Credit Concentration Risk \| Accounts Receivable
Accounting Policies [Line Items]
Number of customers			0		1
Credit Concentration Risk \| Accounts Receivable \| Customer One
Accounting Policies [Line Items]
Concentration risk percentage					12.00%
Minimum \| Credit Concentration Risk \| Accounts Receivable \| Customer One
Accounting Policies [Line Items]
Concentration risk percentage			10.00%

Business Combination - Additional Information (Details) - USD ($) $ in Thousands			1 Months Ended	3 Months Ended
	Apr. 30, 2021	Apr. 16, 2021	Aug. 31, 2020	Jun. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill				$ 320,196	$ 261,116
Scriptcycle LLC
Business Acquisition [Line Items]
Date of acquisition			Aug. 31, 2020
Business combination, aggregate consideration			$ 58,300
Estimated fair value of contingent consideration			800
Contingent consideration based on achievement of certain revenue thresholds			2,900		$ 2,900
Business Combination Contingent Consideration Arrangements Range Of Outcomes Paid				$ 2,900
Goodwill			24,900
Identifiable intangible assets related to acquisition			28,300
Acquired current assets			5,900
Assumed liabilities			1,100
Scriptcycle LLC \| Customer Related Intangible Assets
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition			$ 25,300
Identifiable intangible assets estimated useful life			11 years
Scriptcycle LLC \| Developed Technology and Tradename
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition			$ 3,000
Scriptcycle LLC \| Developed Technology and Tradename \| Minimum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life			1 year
Scriptcycle LLC \| Developed Technology and Tradename \| Maximum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life			9 years
RxSaver, Inc.
Business Acquisition [Line Items]
Date of acquisition	Apr. 30, 2021
Business combination, aggregate consideration	$ 50,700
Goodwill	25,900
Identifiable intangible assets related to acquisition	25,200
Acquired current assets	3,600
Assumed liabilities	4,000
RxSaver, Inc. \| Customer Related Intangible Assets
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition	$ 20,700
Identifiable intangible assets estimated useful life	13 years
RxSaver, Inc. \| Developed Technology and Tradename
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition	$ 4,500
RxSaver, Inc. \| Developed Technology and Tradename \| Minimum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life	1 year
RxSaver, Inc. \| Developed Technology and Tradename \| Maximum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life	3 years
HealthiNation Inc.
Business Acquisition [Line Items]
Date of acquisition		Apr. 16, 2021
Business combination, aggregate consideration		$ 76,600
Goodwill		33,200
Identifiable intangible assets related to acquisition		40,000
Acquired current assets		5,000
Assumed liabilities		1,600
HealthiNation Inc. \| Customer Related Intangible Assets
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition		$ 28,000
Identifiable intangible assets estimated useful life		11 years
HealthiNation Inc. \| Developed Technology and Tradename
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition		$ 600
Identifiable intangible assets estimated useful life		1 year
HealthiNation Inc. \| Content Library
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition		$ 9,500
Identifiable intangible assets estimated useful life		3 years
HealthiNation Inc. \| Order Backlog
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition		$ 1,900
Identifiable intangible assets estimated useful life		1 year

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Prepaid Expense And Other Assets Current [Abstract]
Income taxes receivable	$ 79,797	$ 28,564
Prepaid expenses	14,246	17,484
Total prepaid expenses and other current assets	$ 94,043	$ 46,048

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued bonus and other payroll related	$ 13,500	$ 13,607
Accrued marketing	8,773	10,045
Deferred revenue	8,899	6,852
Other accrued expenses	2,587	7,188
Total accrued expenses and other current liabilities	$ 33,759	$ 37,692

Accrued Expenses and Other Current Liabilities - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Payables And Accruals [Abstract]
Deferred revenue	$ 8,899		$ 8,899		$ 6,852
Revenue recognized	$ 1,400	$ 900	$ 5,700	$ 2,800

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal statutory rate		21.00%
Unrecognized tax benefits			$ 7,400,000
Changes in unrecognized tax benefits	$ 0	$ 0

Debt - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
First Lien Credit Agreement
Debt Instrument [Line Items]
Maximum net leverage ratio			8.20%
Covenant terms			As of June 30, 2021, the Company is subject to a financial covenant requiring maintenance of a Net Leverage Ratio not to exceed 8.2 to 1.0 and other nonfinancial covenants under the First Lien Credit Agreement. Additionally, GoodRx is restricted from making dividend payments, loans or advances to the Company. At June 30, 2021, the Company was in compliance with its covenants.
First Lien Term Loan Facility \| First Lien Credit Agreement
Debt Instrument [Line Items]
Line of credit	$ 700,000		$ 700,000
Percentage of collateralized assets			100.00%
Frequency of interest payment			quarterly
Line of credit maturity date			Oct. 10, 2025
Description of payments			The First Lien Term Loan Facility requires quarterly payments through September 2025, with any unpaid principal and interest due upon maturity on October 10, 2025
Effective interest rate	3.39%	3.83%	3.39%	4.33%
First Lien Term Loan Facility \| Minimum \| First Lien Credit Agreement
Debt Instrument [Line Items]
Interest rate on used amounts			2.75%
First Lien Term Loan Facility \| Maximum \| First Lien Credit Agreement
Debt Instrument [Line Items]
Interest rate on used amounts			3.00%
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit	$ 100,000		$ 100,000
Line of credit maturity date			Oct. 11, 2024
Principal balance	0		$ 0		$ 0
Revolving Credit Facility \| Minimum \| First Lien Credit Agreement
Debt Instrument [Line Items]
Interest rate on used amounts			2.50%
Interest rate on unused amounts			0.25%
Revolving Credit Facility \| Maximum \| First Lien Credit Agreement
Debt Instrument [Line Items]
Interest rate on used amounts			3.00%
Interest rate on unused amounts			0.50%
Letter of Credit
Debt Instrument [Line Items]
Principal balance	$ 9,100		$ 9,100		$ 9,100

Debt - Schedule of Debt (Details) - First Lien Term Loan Facility - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Principal balance	$ 677,611	$ 681,126
Less: Unamortized debt issuance costs and discounts	12,705	(14,209)
Total debt	$ 664,906	$ 666,917

Commitments and Contingencies - Additional Information (Details) $ in Millions	May 27, 2021 USD ($)	Jun. 30, 2021 USD ($)	Apr. 08, 2021 Lawsuit	Mar. 31, 2021 USD ($)
Purchase Commitment Excluding Longterm Commitment [Line Items]
Minimum lease payment	$ 41.4
Lease commencement year	2022
Lease Expiration Year	2033
Number of Lawsuits \| Lawsuit			2
Purchase Commitment
Purchase Commitment Excluding Longterm Commitment [Line Items]
Aggregate purchase commitment minimum amount committed		$ 1.2		$ 3.0

Revenue - Summary of Revenue (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Disaggregation Of Revenue [Line Items]

Revenue

$ 176,635

$ 123,295

$ 337,066

$ 256,703

Prescription Transactions Revenue

Disaggregation Of Revenue [Line Items]

Revenue

144,857

109,548

278,918

232,565

Subscription Revenue

Disaggregation Of Revenue [Line Items]

Revenue

^[1]

14,316

6,358

26,323

11,998

Other Revenue

Disaggregation Of Revenue [Line Items]

Revenue

$ 17,462

$ 7,389

$ 31,825

$ 12,140

[1]	Represents revenue from the Company's Gold and Kroger Savings subscription offerings. Subscription revenue is disclosed separately from other revenue beginning in the second quarter of 2021. Prior period amounts have been recast to conform with the current period presentation.

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted, shares	0		0
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares outstanding, Beginning balance	20,762,000	21,528,000	21,528,000
Granted, shares	0	0
Exercised, shares	(2,609,000)	(513,000)
Expired / Cancelled / Forfeited, shares	(222,000)	(253,000)
Shares outstanding, Ending Balance	17,931,000	20,762,000	17,931,000
Exercisable, Ending Balance	8,756,000		8,756,000
Weighted Average Exercise Prices, Beginning balance	$ 6.24	$ 6.22	$ 6.22
Weighted Average Exercise Prices, granted	0	0
Weighted Average Exercise Prices, Exercised	5.09	5.23
Weighted Average Exercise Prices, Expired/ Cancelled/ Forfeited	7.71	6.07
Weighted Average Exercise Prices, Ending balance	6.39	$ 6.24	6.39
Weighted Average Exercise Prices, Exercisable, Ending Balance	$ 4.36		$ 4.36
Weighted average remaining contractual term, Outstanding	7 years 8 months 12 days	7 years 10 months 24 days
Weighted average remaining contractual term, Exercisable	6 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding	$ 531,079	$ 680,528	$ 531,079
Aggregate Intrinsic Value, Exercisable	$ 277,143		$ 277,143

Stock-Based Compensation - Additional Information (Details) - USD ($)		3 Months Ended			6 Months Ended			12 Months Ended		36 Months Ended
	Sep. 11, 2020	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Dec. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Oct. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		0				0
Weighted-average grant date fair value of stock options granted		$ 3.17					$ 3.04
Aggregate intrinsic value of options exercised		$ 79,900,000		$ 1,000,000.0		$ 98,600,000	$ 2,400,000
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		0	0
Stock-based compensation expense		$ 3,900,000		$ 1,700,000		8,100,000	$ 3,400,000
Unrecognized stock-based compensation cost		26,500,000				$ 26,500,000
Weighted-average period over which cost is expected to be recognized						2 years 6 months
Restricted Stock Units ('RSUs')
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares granted				0			0
Restricted Stock Units ('RSUs') \| Common Class A
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		12,300,000				$ 24,100,000
Unrecognized stock-based compensation cost		131,700,000				$ 131,700,000
Weighted-average period over which cost is expected to be recognized						3 years 4 months 24 days
Restricted Stock Units ('RSUs') \| Common Class B
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 427,000,000.0
Grant date fair value	$ 533,300,000
Restricted Stock Units ('RSUs') \| Common Class B \| Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares granted	24,633,066
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		500,000		$ 400,000		1,000,000.0	$ 900,000
Unrecognized stock-based compensation cost		$ 3,200,000				$ 3,200,000
Weighted-average period over which cost is expected to be recognized							1 year 9 months 18 days
Restricted shares granted		0	0						0
Restricted shares outstanding		939,000	1,409,000			939,000		1,409,000
Shares vested		470,000	0
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards \| Common Class B
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 319,800,000
Shares vested								16,422,044
Shares for tax withholding obligations								700,000
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards \| Common Class B \| Forecast
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining shares not issued until three years from vesting date										15,700,000
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards \| Common Class B \| Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares vested	8,211,022
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards \| Common Class B \| Co-Chief Executive Officers \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 6.07
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards \| Common Class B \| Co-Chief Executive Officers \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 51.28
Restricted Stock Units ("RSUs") Time-Vesting Founders Awards \| Common Class B
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 107,200,000	$ 24,000,000.0				$ 54,000,000.0
Unrecognized stock-based compensation cost		$ 106,300				$ 106,300
Weighted-average period over which cost is expected to be recognized						1 year 10 months 24 days
Restricted Stock Units ("RSUs") Time-Vesting Founders Awards \| Common Class B \| Forecast
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense					$ 36,900,000
Restricted Stock Units ("RSUs") Time-Vesting Founders Awards \| Common Class B \| Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares vested and settled	4,105,511
Vesting period	4 years

Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - $ / shares shares in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2019
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	1,409	1,409
Granted	0	0	0
Vested	(470)	0
Forfeited	0	0
Nonvested restricted stock awards or restricted stock units, Ending Balance	939	1,409
Restricted Stock Units for Class A Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	3,325	2,790
Granted	618	647
Vested	(118)	(95)
Forfeited	(67)	(17)
Nonvested restricted stock awards or restricted stock units, Ending Balance	3,758	3,325
Restricted Stock Units for Class B Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	7,185	7,698
Granted	0	0
Vested	(513)	(513)
Forfeited	0	0
Nonvested restricted stock awards or restricted stock units, Ending Balance	6,672	7,185
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Weighted Average Grant Date Fair Value, Beginning Balance	$ 28.05	$ 26.74
Granted, Weighted Average Grant Date Fair Value	37.86	44.12
Vested, Weighted Average Grant Date Fair Value	18.68	29.12
Forfeited, Weighted Average Grant Date Fair Value	36.61	42.31
Nonvested restricted stock awards or restricted stock units, Weighted Average Grant Date Fair Value, Ending Balance	$ 29.44	$ 28.05

Basic and Diluted Earnings Per Share - Schedule Computation of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Net income	$ 31,061	$ 1,668	$ 27,337	$ 27,346	$ 32,729	$ 54,683
Less: Undistributed earnings allocated to convertible preferred stock	0		(9,674)		0	(19,358)
Net income attributable to common stockholders - basic	31,061		17,663		32,729	35,325
Add: Undistributed earnings reallocated to holders of common stock	0		179		0	349
Net income attributable to common stockholders - diluted	$ 31,061		$ 17,842		$ 32,729	$ 35,674
Denominator:
Weighted average shares - basic	408,363		230,160		407,273	230,020
Dilutive impact of stock options, restricted stock awards and restricted stock units	20,504		6,730		21,955	6,537
Weighted average shares - diluted	428,867		236,890		429,228	236,557
Earnings per share:
Basic	$ 0.08		$ 0.08		$ 0.08	$ 0.15
Diluted	$ 0.07		$ 0.08		$ 0.08	$ 0.15

Basic and Diluted Earnings Per Share - Weighted-Average Potentially Dilutive Shares Were Excluded From Computation of Diluted Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares were excluded from computation of diluted earnings per share		0	126,046	0	126,046
Stock Options, Restricted Stock Awards and Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares were excluded from computation of diluted earnings per share	3,277		11,556	1,904	11,309

Subsequent Events - Additional Information (Details) - USD ($) $ in Millions			3 Months Ended	6 Months Ended
	Jul. 21, 2021	Jul. 07, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Restricted Stock Units ('RSUs')
Subsequent Event [Line Items]
Restricted shares granted			0		0
Restricted Stock Units ('RSUs') \| Class A Common Stock
Subsequent Event [Line Items]
Unrecognized stock-based compensation cost				$ 131.7
Weighted-average period over which cost is expected to be recognized				3 years 4 months 24 days
Subsequent Event
Subsequent Event [Line Items]
Unrecognized stock-based compensation cost	$ 15.2
Subsequent Event \| Restricted Stock Units ('RSUs') \| Class A Common Stock
Subsequent Event [Line Items]
Restricted shares granted	500,000
Subsequent Event \| Board of Directors \| Restricted Stock Units ('RSUs')
Subsequent Event [Line Items]
Vesting period	4 years
Weighted-average period over which cost is expected to be recognized	4 years
Subsequent Event \| HealthiNation Inc.
Subsequent Event [Line Items]
Business combination, consideration paid in cash		$ 14.5